Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
04/1999
04/01/1999WO1999015493A1 9,10-dihydro-9,10-ethanoanthracene derivatives as phospholipase inhibitors
04/01/1999WO1999015487A1 Benzyl-biphenyls and analogous compounds and the application thereof in order to treat arteriosclerosis and dyslipidaemia
04/01/1999WO1999015178A1 Vitronectin receptor antagonist
04/01/1999WO1999015170A1 Vitronectin receptor antagonist
04/01/1999WO1999015169A1 Thrombin inhibitors
04/01/1999WO1999015164A1 Amide derivatives for the treatment of diseases mediated by cytokines
04/01/1999WO1999003878A3 Inhibitors of metalloproteinases, their therapeutic use, and process for the production of the starting compound in their synthesis
04/01/1999WO1999002497A3 Pyridine derivatives
04/01/1999WO1998054301A3 Transplants for myocardial scars and method and cellular preparations therefor
04/01/1999WO1998051321A9 Tissue factor for influencing blood vessel formation
04/01/1999WO1998024482A3 Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them
04/01/1999DE19743143A1 Pharmazeutische Kombinationspräparate Pharmaceutical combination preparations
04/01/1999DE19742717A1 Synergistic combination of endothelin antagonist and renin-angiotensin system inhibitor
04/01/1999CA2304879A1 New tetracycles, process for their production and pharmaceutical preparations containing these compounds
04/01/1999CA2304849A1 Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors
04/01/1999CA2304274A1 Benzyl-biphenyls and analogous compounds and the application thereof in order to treat arteriosclerosis and dyslipidaemia
04/01/1999CA2304000A1 Vitronectin receptor antagonist
04/01/1999CA2303994A1 N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives
04/01/1999CA2303943A1 2-aminotetralines, a process for their preparation, and pharmaceutical compositions, for the prevention and therapeutic treatment of inflammatory and/or autoimmune pathologies
04/01/1999CA2303846A1 Vitronectin receptor antagonist
04/01/1999CA2303528A1 New npy antagonists
04/01/1999CA2303487A1 Vitronectin receptor antagonists
04/01/1999CA2302572A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
04/01/1999CA2301614A1 Thrombin inhibitors
04/01/1999CA2300051A1 Amide derivatives for the treatment of diseases mediated by cytokines
04/01/1999CA2246004A1 A kringle-related clone, hthbz47
03/1999
03/31/1999EP0905249A2 Alcohol dehydrogenase
03/31/1999EP0905248A1 Staphylococcus aureus MurE protein and nucleic acids encoding it
03/31/1999EP0905243A2 Polynucleotides from Staphylococcus aureus expressed in infected tissue
03/31/1999EP0905139A2 5 ring heterocyles, process for preparation, use as inhibitors of leukocyte adhesion and pharmaceutical preparations comprising them
03/31/1999EP0905136A1 Tetrahydro gamma-carbolines
03/31/1999EP0905131A1 Sulfonamid-substituted chromans, process for their preparation, their use as medicine, and pharmaceutical preparation containing them
03/31/1999EP0905126A1 Metalloproteinase inhibitors
03/31/1999EP0904543A1 Use of rc-9 in diagnosis and treatment of proliferative arterial disease
03/31/1999EP0904287A2 Cytokine designated lerk-8
03/31/1999EP0904284A1 6-substituted amino-4-oxa-1-azabicyclo (3,2,0) heptan-7-one derivatives as cysteine protease inhibitors
03/31/1999EP0904277A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease
03/31/1999EP0904260A1 Inhibition of matrix metalloproteases by 2-(omega-aroylalkyl)-4-biaryl-oxobutyric acids
03/31/1999EP0904110A1 Nitric oxide donors capable of reducing toxicity from drugs
03/31/1999EP0904097A2 Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
03/31/1999EP0904082A1 Combination therapy for reducing the risks associated with cardiovascular disease
03/31/1999EP0904080A1 Inhibitors of farnesyl-protein transferase
03/31/1999EP0904079A1 Antidiabetic agents
03/31/1999EP0904078A1 COMPOSITION COMPRISING A Katp CHANNEL INHIBITOR FOR USE IN THE TREATMENT OF HEMORRHAGIC SHOCK
03/31/1999EP0904077A2 Methods for the preparation of biphenyl isoxazole sulfonamides
03/31/1999EP0904076A1 Inhibitors of farnesyl-protein transferase
03/31/1999EP0904069A1 Pla2 inhibitors of angiogenesis
03/31/1999EP0877025A4 Substituted 6-h-1,3,4-thiadiazine-2-amines, the use thereof as anaesthetising, cardiovascular and hypometabolic agents, and a pharmaceutical composition containing them
03/31/1999EP0714395B1 Vasoconstrictive substituted dihydropyranopyridines
03/31/1999CN1212705A Serine protease inhibitors
03/31/1999CN1212704A Serine protease inhibitors
03/31/1999CN1212684A 4-anilinoquinazoline derivatives
03/31/1999CN1212622A Use of antagnoist of PPAR-alpha and PPAR-gamma for treatment of syndrom X
03/31/1999CN1212620A Mercapto derivatives as inhibitors of cyclooxygenases
03/31/1999CN1212150A Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in blood to reduce risk of athereosclerosis and vascular disease
03/31/1999CN1212132A Tartaric acid nutritious honey capable of balancing blood pressure
03/31/1999CN1042730C Method for preparing pyrazolopyridine compound
03/30/1999US5889178 N-(2,2-diphenylethyl)-derivatives
03/30/1999US5889060 Therapeutic use of(R)-Verapamil for treating angina
03/30/1999US5889056 Of nitric oxide synthase; hypotensive agent, antiinflammatory agents, antiarthritic agents
03/30/1999US5889049 Use of terpene compounds for reduced release of arachidonic acid and of inflammation mediators
03/30/1999US5889046 Method for preventing or alleviating cerebral apoplexy
03/30/1999US5889042 Method of treating diseases and conditions with estrogen agonists and antagonists
03/30/1999US5889037 Prevention, therapy tissue damage from lipid peroxidation
03/30/1999US5889022 Psychological disorders
03/30/1999US5889002 Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
03/30/1999US5889000 Naphthofluorene compounds, intermediates, compositions and methods
03/30/1999US5888972 Endothelin antagonist
03/30/1999US5888770 Spoiiie
03/30/1999US5888506 A detergent free polypeptide in the form of crystal structure or lyophilized or conjugated with polyoxyethylene glycol and contains less than 1 ng endotoxin per mg protein
03/30/1999CA2157927C Therapeutic uses of bactericidal/permeability increasing protein produc ts
03/26/1999CA2249074A1 Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them
03/25/1999WO1999014346A2 SENSE mRNA THERAPY
03/25/1999WO1999014340A1 Human prl-1 phosphatase
03/25/1999WO1999014215A1 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
03/25/1999WO1999014213A1 Substituted chroman derivatives
03/25/1999WO1999014212A1 Substituted chroman derivatives
03/25/1999WO1999014207A1 Substituted indan derivatives
03/25/1999WO1999014199A1 Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine-10-oles, method for the production and use thereof as medicaments
03/25/1999WO1999013920A2 Method for treating proliferative diseases by therapy
03/25/1999WO1999013910A1 Neovascularization inhibitor
03/25/1999WO1999013890A1 Treatment of stress and preconditioning against stress
03/25/1999WO1999003822A8 Bicyclic metabotropic glutamate receptor ligands
03/25/1999WO1998050032A9 BETA-LACTAM INHIBITORS OF CoA-IT
03/25/1999WO1998048027A3 Materials and methods for treatment of retinal diseases
03/25/1999WO1998048009A3 Materials and methods for ribozyme treatment of retinal diseases
03/25/1999DE19742014A1 Use of new and known tetracyclene compounds as phospholipase inhibitors
03/25/1999DE19741400A1 New benzyl-biphenyl derivatives
03/25/1999DE19741399A1 New tetrahydroquinoline derivatives useful in treatment of elevated lipid levels and arteriosclerosis
03/25/1999DE19741051A1 New tetrahydroquinoline derivatives useful in treatment of raised lipid levels and arteriosclerosis
03/25/1999CA2304982A1 Sense mrna therapy
03/25/1999CA2304037A1 Substituted chroman derivatives
03/25/1999CA2303926A1 Substituted chroman derivatives
03/25/1999CA2303839A1 Substituted indan derivatives
03/25/1999CA2303227A1 Human prl-1 phosphatase
03/25/1999CA2301887A1 Method for treating proliferative diseases by therapy
03/25/1999CA2244978A1 Novel alcohol dehydrogenase
03/25/1999CA2244971A1 Mure
03/24/1999EP0903353A1 Imidazolidine derivates, their preparation and use, and pharmaceutical compositions containing them
03/24/1999EP0903143A2 Use of daidzein for the manufacture of a medicament for incraesing HDL cholesterol levels
1 ... 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 ... 1595